Ariana Pelosci

Articles

First-Line Nivolumab Plus Chemotherapy Shows Real-World Efficacy in Gastric/GEJ/Esophageal Cancers

January 18th 2024

Real-world findings demonstrated a favorable survival benefit with nivolumab plus chemotherapy in advanced gastroesophageal adenocarcinoma.

Redefining Research Practices in Search of a Cure

January 2nd 2024

Fernando Cabanillas, MD, a mentor and leader in the lymphoma field, is being recognized for his contributions to the hematologic oncology space.

Axi-Cel Provides Sustained Response in High-Risk Large B-cell Lymphoma

December 12th 2023

Patients with high-risk large B-cell lymphoma experienced durable responses when treated with first-line axicabtagene ciloleucel, according to results from the phase 2 ZUMA-12 trial.

Ultrasensitive BCMA CARs Deliver Responses With Tolerable Safety in R/R Multiple Myeloma

December 10th 2023

The use of the BCMA-directed CAR T-cell therapy D8 Fab CAR and the dual-targeting AUTO8 CAR T-cell therapy is safe and feasible in patients with relapsed/refractory multiple myeloma.

AI Assistance Proves Safe, Decreases Time and Cost Burden of Sentinel Lymph Node Detection in Metastatic Breast Cancer

December 6th 2023

Utilizing an artificial intelligence–assisted workflow to detect sentinel lymph node metastases in patients with breast cancer was deemed safe according to current diagnostic standards and reduced the need for immunohistochemistry and its associated financial burden.

Trastuzumab Deruxtecan Sustains Survival Benefits in HER2-Low Metastatic Breast Cancer

October 21st 2023

Treatment with fam-trastuzumab deruxtecan-nxki led to sustained improvements in overall survival and progression-free survival vs physician’s choice of treatment in patients with previously treated HER2-low metastatic breast cancer, irrespective of hormone receptor status.

Senaparib Maintenance Generates PFS Benefit in Advanced Ovarian Cancer

October 20th 2023

Maintenance therapy consisting of single-agent senaparib reduced the risk of progression or death vs placebo in patients with newly diagnosed advanced ovarian cancer, irrespective of BRCA mutation status.

Teclistamab Delivers Comparable Efficacy Between Real-World and MajesTEC-1 Myeloma Populations

September 29th 2023

Treatment with teclistamab-cqyv in real-world patients with relapsed/refractory multiple myeloma elicited similar efficacy results and a comparable safety profile to findings from the phase 1/2 Majes-TEC-1 trial.

Daratumumab Plus Ixazomib and Dexamethasone Produces Significant Responses in R/R Multiple Myeloma

June 9th 2023

The combination of daratumumab, ixazomib, and dexamethasone produced rapid and encouraging responses rates following lenalidomide–based therapy in patients with relapsed/refractory multiple myeloma, according to findings from the final analysis of the phase 2 DARIA trial.

HER3-DXd Elicits Responses and Safety in Heavily Pretreated ER+ Breast Cancer and TNBC

June 5th 2023

Patritumab deruxtecan displayed manageable safety and produced responses in heavily pretreated patients with estrogen receptor–positive or triple-negative metastatic breast cancer with varying levels of HER3 expression, according to data from a phase 2 study presented at the 2023 ASCO Annual Meeting.

Zanidatamab Elicits Responses in HER2-amplified Advanced Biliary Tract Cancer

June 3rd 2023

Zanidatamab generated responses in patients with HER2-amplified, locally advanced, unresectable or metastatic biliary tract cancer who were previously treated with gemcitabine.

Olaparib Plus Selumetinib Produces Clinical Benefit in RAS-Mutated Ovarian and Endometrial Cancer

March 27th 2023

The recommended phase 2 dose of olaparib plus selumetinib generated a clinical benefit in patients with endometrial or ovarian cancer harboring RAS mutations, according to findings from the dose-expansion portion of the phase 1b SOLAR trial.

Nivolumab Plus Salvage Immunotherapy Leads to High TFS Rates in Advanced RCC

February 21st 2023

Nivolumab monotherapy, plus salvage nivolumab plus ipilimumab for progressive disease, resulted in high treatment-free survival rates in patients with previously untreated advanced clear cell renal cell carcinoma.

HER2-Low Classification Is Associated With Distinct Clinical Features in Advanced Gastric Cancer

January 19th 2023

Clinicopathological features of HER2-low advanced gastric cancer were distinct and distinguishable from those of HER2-positive or -negative disease, according to retrospective findings from a single-institution study that were presented at the 2022 Gastrointestinal Cancers Symposium.

Tisagenlecleucel Elicits Sustained Responses in Relapsed/Refractory Follicular Lymphoma

December 12th 2022

Tisagenlecleucel produced durable responses in patients with relapsed/refractory follicular lymphoma, including those with high-risk disease characteristics.

Rituximab/Lenalidomide Shows Sustained PFS Benefit in Indolent Non-Hodgkin Lymphoma

December 10th 2022

The combination of rituximab and lenalidomide maintained improved progression-free survival compared with rituximab alone in patients with relapsed/refractory indolent non-Hodgkin lymphoma, according to 5-year findings from the phase 3 AUGMENT trial.

Capivasertib Plus Fulvestrant Elicits PFS Benefit in HR+/HER2- Advanced Breast Cancer

December 8th 2022

The combination of capivasertib plus fulvestrant significantly improved progression-free survival vs fulvestrant alone in patients with hormone receptor–positive/HER2-negative advanced breast cancer, including those with AKT pathway–altered tumors.

Pembrolizumab/Olaparib Combo Fails to Improve rPFS, OS Vs Novel Hormonal Agents in mCRPC

September 12th 2022

The combination of pembrolizumab and olaparib did not significantly improve radiographic progression-free survival and overall survival compared with novel hormonal agents in patients with molecularly unselected, previously treated metastatic castration-resistant prostate cancer.

Preoperative Nivolumab Alone or With Relatlimab Allows for Surgical Feasibility in Resectable NSCLC

September 9th 2022

Preoperative nivolumab with or without relatlimab increased surgical feasibility in patients with resectable non–small cell lung cancer.

Sintilimab Elicits Similar Efficacy, Safety Vs Pembrolizumab in Advanced NSCLC

August 7th 2022

Sintilimab, both as a single agent and in combination with chemotherapy, generated comparable efficacy and safety vs pembrolizumab in patients with untreated metastatic non–small cell lung cancer.